Drug‐coated stents: Preventing restenosis in coronary artery disease

Journal of Cardiovascular Nursing

Volumn 19, Issue 6, 2004, Pages 404-408

  Stanik Hutt, Julie A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Drug eluting; Paclitaxel; Percutaneous coronary intervention; Restenosis; Sirolimus; Stents

Indexed keywords

BIOMATERIAL; PACLITAXEL; RAPAMYCIN;

COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; HEART INFARCTION; HUMAN; PATIENT SELECTION; REGISTER; RESTENOSIS; REVIEW; STANDARD; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL INFARCTION; PACLITAXEL; PATIENT SELECTION; REGISTRIES; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 16644379890     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200411000-00012     Document Type: Article

References (49)

1. Fattori R, Piva T. Drug eluting stents in vascular intervention. Lancet. 2003;361:247-249.
2. Sousa J, Costa M, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus coated stents in human coronary arteries: a quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
3. Sousa J, Serruys P, Costa M. New frontiers in cardiology: drug eluting stents. Circulation. 2003;107(pt 1):2274-2279.
4. Sousa J, Serruys P, Costa M. New frontiers in cardiology: drug eluting stents. Circulation. 2003;107(pt 2): 2383-2389.
5. Rajagopal V, Pockson S. Coronary restenosis: a review of mechanisms and management. Am J Med. 2003;115: 547-553.
6. Huang Y, Salu K, Liu Z, et al. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart. 2004;90:195-199.
7. Farb A, Heller P, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer coated stent. Circulation. 2001;104:473-479.
8. Park S, Shim W, Ho D, et al. A paclitaxel eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
9. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel eluting, polymer free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109: 487-493.
10. Instructions for Use: Cypher Sirolimus-eluting Coronary Stent on RAPTOR Over-the-Wire Delivery System. Miami, Fla: Cordis Corporation; 2003.
11. Taxus Express Paclitaxel-eluting Coronary Stent System: Instructions for Use. Natick, Mass: Boston Scientific Corporation; 2004.
12. Schwertz D, Zaitkus P. Drug eluting stents to prevent reblockage of coronary arteries. J Cardiovasc Nur. 2003; 18:11-16.
13. Faxon D. Bringing reality to drug eluting stents. Circulation. 2004;109:140-142.
14. Sousa J, Costa M, Sousa A, et al. Two year angiographic and intravascular ultrasound follow up after implantation of sirolimus eluting stents in human coronary arteries. Circulation. 2003;107:381.
15. Sousa J, Sousa A, Costa M, Abizaid A, Feres F. Use of rapamycin impregnated stents in coronary arteries. Transplant Proc. 2003;35(supp 1)S165-S170.
16. Moses J, Leon M, Popma J, et al. Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
17. Grube E, Silber S, Hauptmann K, et al. TAXUS I: six and twelve month results from a randomized, double blind trial on a slow release paclitaxel eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
18. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow and moderate release polymer based paclitaxel eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
19. Hong M, Mintz G, Lee C, et al. Paclitaxel coating reduces in stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel Eluting stent Clinical Trial (ASPECT). Circulation. 2003;107:517-520.
20. Stone G, Ellis S, Cox D, et al. A polymer based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
21. Lansky A, Costa R, Mintz G, et al. Non-polymer-based paclitaxel coated coronary stents for the treatment of patients with de novo coronary lesions: Angiographic follow-up of the DELIVER clinical trial. Circulation. 2004; 109:1948-1954.
22. Holmes D, Leon M, Moses J, et al. Analysis of 1 year clinical outcomes in the SIRIUS trial. Circulation. 2004;109: 634-640.
23. Schofer J, Schluter M, Gershlick A, et al. Sirolimus eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362: 1093-1099.
24. Schampaert E, Cohen E, Schluter M, et al. The Canadian study of the sirolimus eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43: 1110-1115.
25. Lemos P, Arampatzis C, Saia F, et al. Treatment of very small vessels with 2.25 mm diameter sirolimus eluting stents (from the RESEARCH registry). Am J Cardiol. 2004;93:633-636.
26. Keeley E, Aliabadi D, O'Neill W, Safian R. Immediate and long term results of elective and emergent percutaneous interventions on protected and unprotected severely narrowed left main coronary arteries. Am J Cardiol. 1999; 83:242-246.
27. Takagi T, Stankovic G, Finci L, et al. Results and long term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation. 2002;106:698-702.
28. Arampatzis C, Lemos P, Tanabe K, et al. Effectiveness of sirolimus eluting stent for treatment of left main coronary artery disease. Am J Cardiol. 2003;92:327-329.
29. Stone G, Grines C, Cox D, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infraction. N Engl J Med. 2002;346: 957-966.
30. Lemos P, Lee C, Degertekin M, et al. Early outcome after sirolimus eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 2003;41:1927-1929.
31. Saia F, Lemos P, Lee D, et al. Sirolimus eluting stent implantation in ST-elevation acute myocardial infarction. Circulation. 2003;108:1927-1929.
32. Grines C, Cox D, Stone G, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949-1956.
33. Lemos P, Saia F, Hofma S, et al. Short and long term clinical benefit of sirolimus eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43: 704-708.
34. Waksman R, Raizner A, Yeung A, Lansky A, Vandertie L. Use of localized intracoronary beta radiation in treatment of in stent restenosis: the INHIBIT randomized controlled trial. Lancet. 2002;359:551-557.
35. Lowe H, Oesterle S, Khachigian L. Coronary in stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39:183-193.
36. Waksman R, White R, Chan R, et al. Intracoronary gamma radiation therapy after angioplasty inhibits recurrence in patients with in stent restenosis. Circulation. 2000;101:2165-2171.
37. Leon M, Teirstein P, Moses J, et al. Localized intracoronary gamma radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344: 250-256.
38. Tanabe K, Serruys P, Grube E, et al. TAXUS III trial: in stent restenosis treated with stent based delivery of paclitaxel incorporated in a slow release polymer formulation. Circulation. 2003;107:559-564.
39. Hoffmann R, Langenberg R, Radke P, et al. Treatment of in stent restenosis using a stent with non polymer based paclitaxel elution. Am J Cardiol. 2004;93:760-762.
40. Degertekin M, Regar E, Tanabe K, et al. Sirolimus eluting stent for treatment of complex in stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003;41: 184-189.
41. Sousa J, Costa M, Abizaid A, et al. Sirolimus eluting stent for the treatment of in stent restenosis: a quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation. 2003;107:24-27.
42. Degertekin M, Lemos P, Lee C, et al. Intravascular ultrasound evaluation after Sirolimus eluting stent implantation for de novo and in stent restenosis lesions. Eur Heart J. 2004;25:32-38.
43. Saia F, Lemos P, Sianos G, et al. Effectiveness of Sirolimus eluting stent implantation for recurrent in stent restenosis after brachytherapy. Am J Cardiol. 2003;92:200-203.
44. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcomes after coronary stent placement. J Am Coll Cardiol. 1998;32:1866-1873.
45. Abizaid A, Costa M, Blanchard D, et al. Sirolimus eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial. Eur Heart J. 2004;25: 107-112.
46. Lemos P, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus eluting stent implantation in complex patients: an evaluation from the Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109:1366-1370.
47. Lemos P, Serruys P, van Domburg R, et al. Unrestricted utilization of sirolimus eluting stents compared with conventional bare stent implantation in the “real world.” The Rapamycin Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195.
48. Bhatia V, Bhatia R, Dhindsa S. Drug eluting intra coronary stents: have we got the magic bullet? J Postgrad Med. 2003;49:291-296.
49. Guagliumi G, Musumeci G, Vassileva A, Tespili M, Vasecchi O. Through the drug eluting stent labyrinth. Ital Heart J. 2003;4(4):236-245.